Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-12

AUTHORS

Timo Purmonen, Kari Puolakka, Devarshi Bhattacharyya, Minal Jain, Janne Martikainen

ABSTRACT

Objective: To study cost-effectiveness of an interleukin (IL)-17A inhibitor secukinumab, with other biologics and apremilast in patients with Psoriatic arthritis (PsA) from payer perspective in Finland. Methods: In this semi-Markov model, subcutaneous (SC) secukinumab was compared with SC treatments etanercept and its biosimilar, certolizumab pegol, adalimumab and its biosimilar, golimumab, ustekinumab, intravenous (IV) treatment infliximab, as well as oral non-biologic apremilast. Patients without prior exposure (naïve) to biologics and without moderate to severe psoriasis were considered for secukinumab 150 mg group. Secukinumab 300 mg group included naïve patients with moderate to severe psoriasis and all patients with prior biologic exposure. The PsA Response Criteria (PsARC) at 12-week was primary criteria for treatment response. Other clinical as well as cost related model inputs were derived from relevant clinical trials as well as Finnish publications. The key model outcomes were quality-adjusted life years and incremental cost-effectiveness ratio. An annual 3% discount rate was applied to all future costs and benefits. Model input variations were assessed through sensitivity analyses and alternative scenario analyses. Results: For a lifetime horizon (60 years), secukinumab 150 mg dominated all branded SC biologics and apremilast with highest QALY of 8.01 and lowest lifetime cost of €187,776, while it was cost-effective against IV infliximab among biologic-naïve patients without moderate to severe psoriasis. Secukinumab 300 mg was cost-effective against all branded SC biologics and apremilast and dominated IV infliximab among biologic-naïve patients with moderate to severe psoriasis, while it was cost-effective in biologic experienced patients. With the one-way sensitivity analysis, PsARC response, drug acquisition cost, and health assessment questionnaire score were the most important parameters affecting the outcomes. Across all treatment groups, patients on secukinumab were most likely to achieve highest net monetary benefit than other competitors in probabilistic sensitivity analysis. With alternative scenario analysis, results largely remained unchanged. Conclusions: Secukinumab is a cost-effective treatment for PsA patients from a Finnish payer's perspective. More... »

PAGES

56

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12962-018-0162-3

DOI

http://dx.doi.org/10.1186/s12962-018-0162-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1109928536

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30479574


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1402", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Applied Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/14", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Economics", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Novartis Finland Oy, Espoo, Finland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Purmonen", 
        "givenName": "Timo", 
        "id": "sg:person.01077653263.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077653263.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Etel\u00e4-Karjalan sosiaali ja terveyspiiri", 
          "id": "https://www.grid.ac/institutes/grid.434312.3", 
          "name": [
            "South Karelia Social and Health Care District, Lappeenranta, Finland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Puolakka", 
        "givenName": "Kari", 
        "id": "sg:person.01337337404.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01337337404.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (India)", 
          "id": "https://www.grid.ac/institutes/grid.464975.d", 
          "name": [
            "Novartis Product Life Cycle Services-NBS, Novartis Healthcare Private Limited, Hyderabad, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bhattacharyya", 
        "givenName": "Devarshi", 
        "id": "sg:person.015705523615.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015705523615.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (India)", 
          "id": "https://www.grid.ac/institutes/grid.464975.d", 
          "name": [
            "Novartis Product Life Cycle Services-NBS, Novartis Healthcare Private Limited, Hyderabad, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jain", 
        "givenName": "Minal", 
        "id": "sg:person.01065642027.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065642027.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Eastern Finland", 
          "id": "https://www.grid.ac/institutes/grid.9668.1", 
          "name": [
            "School of Pharmacy, University of Eastern Finland, Kuopio, Finland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Martikainen", 
        "givenName": "Janne", 
        "id": "sg:person.01015641310.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01015641310.65"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s40744-016-0029-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002336273", 
          "https://doi.org/10.1007/s40744-016-0029-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40744-016-0029-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002336273", 
          "https://doi.org/10.1007/s40744-016-0029-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/ard.2004.032482", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002609767"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1365-2133.2002.04920.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005696098"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.39573", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005700908"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3899/jrheum.160275", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008779147"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2011-200350", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009950017"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2474-15-26", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011167965", 
          "https://doi.org/10.1186/1471-2474-15-26"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2014-206418", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013200417"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40271-014-0075-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015256079", 
          "https://doi.org/10.1007/s40271-014-0075-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jval.2015.09.2852", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015684295"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/acr.23111", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019018398"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jval.2010.10.016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020791101"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2015-208337", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022767391"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/rheumatology/keg107", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026122648"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3899/jrheum.100069", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030409323"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2012-202424", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030930080"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/rheumatology/ker245", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033865184"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1412679", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035341201"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/ard.2008.094946", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035839107"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10198-011-0335-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037467100", 
          "https://doi.org/10.1007/s10198-011-0335-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/2193-1801-2-531", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039556570", 
          "https://doi.org/10.1186/2193-1801-2-531"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(15)61134-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040399320"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10067-016-3425-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042078868", 
          "https://doi.org/10.1007/s10067-016-3425-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10067-016-3425-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042078868", 
          "https://doi.org/10.1007/s10067-016-3425-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/rheumatology/kem221", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042257987"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40265-014-0191-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052835422", 
          "https://doi.org/10.1007/s40265-014-0191-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40265-014-0191-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052835422", 
          "https://doi.org/10.1007/s40265-014-0191-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00005650-199711000-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060223465"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00005650-199711000-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060223465"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00005650-199711000-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060223465"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00005650-199711000-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060223465"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2016-eular.2465", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062760399"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2016-eular.2465", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062760399"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/2040622315582354", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064083933"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/2040622315582354", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064083933"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3310/hta10310", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071138932"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3310/hta15100", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071139223"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3899/jrheum.091315", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071542120"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1076612913", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078323662", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079165331", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/13696998.2017.1384737", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091933859"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/rheumatology/kex452", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092758382"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrrheum.2017.188", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092816761", 
          "https://doi.org/10.1038/nrrheum.2017.188"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2017-eular.1260", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1095975872"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2017-eular.1260", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1095975872"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2217/cer-2018-0075", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107093501"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-12", 
    "datePublishedReg": "2018-12-01", 
    "description": "Objective: To study cost-effectiveness of an interleukin (IL)-17A inhibitor secukinumab, with other biologics and apremilast in patients with Psoriatic arthritis (PsA) from payer perspective in Finland.\nMethods: In this semi-Markov model, subcutaneous (SC) secukinumab was compared with SC treatments etanercept and its biosimilar, certolizumab pegol, adalimumab and its biosimilar, golimumab, ustekinumab, intravenous (IV) treatment infliximab, as well as oral non-biologic apremilast. Patients without prior exposure (na\u00efve) to biologics and without moderate to severe psoriasis were considered for secukinumab 150\u00a0mg group. Secukinumab 300\u00a0mg group included na\u00efve patients with moderate to severe psoriasis and all patients with prior biologic exposure. The PsA Response Criteria (PsARC) at 12-week was primary criteria for treatment response. Other clinical as well as cost related model inputs were derived from relevant clinical trials as well as Finnish publications. The key model outcomes were quality-adjusted life years and incremental cost-effectiveness ratio. An annual 3% discount rate was applied to all future costs and benefits. Model input variations were assessed through sensitivity analyses and alternative scenario analyses.\nResults: For a lifetime horizon (60\u00a0years), secukinumab 150\u00a0mg dominated all branded SC biologics and apremilast with highest QALY of 8.01 and lowest lifetime cost of \u20ac187,776, while it was cost-effective against IV infliximab among biologic-na\u00efve patients without moderate to severe psoriasis. Secukinumab 300\u00a0mg was cost-effective against all branded SC biologics and apremilast and dominated IV infliximab among biologic-na\u00efve patients with moderate to severe psoriasis, while it was cost-effective in biologic experienced patients. With the one-way sensitivity analysis, PsARC response, drug acquisition cost, and health assessment questionnaire score were the most important parameters affecting the outcomes. Across all treatment groups, patients on secukinumab were most likely to achieve highest net monetary benefit than other competitors in probabilistic sensitivity analysis. With alternative scenario analysis, results largely remained unchanged.\nConclusions: Secukinumab is a cost-effective treatment for PsA patients from a Finnish payer's perspective.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12962-018-0162-3", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1032048", 
        "issn": [
          "1478-7547"
        ], 
        "name": "Cost Effectiveness and Resource Allocation", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "16"
      }
    ], 
    "name": "Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective", 
    "pagination": "56", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "da46f47df5e79cae6a40a9a70b6a669200c3c56d3ddbf83854de43d0f932ac54"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30479574"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101170476"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12962-018-0162-3"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1109928536"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12962-018-0162-3", 
      "https://app.dimensions.ai/details/publication/pub.1109928536"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T08:13", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000274_0000000274/records_37026_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs12962-018-0162-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12962-018-0162-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12962-018-0162-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12962-018-0162-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12962-018-0162-3'


 

This table displays all metadata directly associated to this object as RDF triples.

226 TRIPLES      21 PREDICATES      68 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12962-018-0162-3 schema:about anzsrc-for:14
2 anzsrc-for:1402
3 schema:author N8f8f442ee9f24e068eb70473b22eb074
4 schema:citation sg:pub.10.1007/s10067-016-3425-4
5 sg:pub.10.1007/s10198-011-0335-x
6 sg:pub.10.1007/s40265-014-0191-y
7 sg:pub.10.1007/s40271-014-0075-y
8 sg:pub.10.1007/s40744-016-0029-z
9 sg:pub.10.1038/nrrheum.2017.188
10 sg:pub.10.1186/1471-2474-15-26
11 sg:pub.10.1186/2193-1801-2-531
12 https://app.dimensions.ai/details/publication/pub.1076612913
13 https://app.dimensions.ai/details/publication/pub.1078323662
14 https://app.dimensions.ai/details/publication/pub.1079165331
15 https://doi.org/10.1002/acr.23111
16 https://doi.org/10.1002/art.39573
17 https://doi.org/10.1016/j.jval.2010.10.016
18 https://doi.org/10.1016/j.jval.2015.09.2852
19 https://doi.org/10.1016/s0140-6736(15)61134-5
20 https://doi.org/10.1046/j.1365-2133.2002.04920.x
21 https://doi.org/10.1056/nejmoa1412679
22 https://doi.org/10.1080/13696998.2017.1384737
23 https://doi.org/10.1093/rheumatology/keg107
24 https://doi.org/10.1093/rheumatology/kem221
25 https://doi.org/10.1093/rheumatology/ker245
26 https://doi.org/10.1093/rheumatology/kex452
27 https://doi.org/10.1097/00005650-199711000-00002
28 https://doi.org/10.1136/annrheumdis-2011-200350
29 https://doi.org/10.1136/annrheumdis-2012-202424
30 https://doi.org/10.1136/annrheumdis-2014-206418
31 https://doi.org/10.1136/annrheumdis-2015-208337
32 https://doi.org/10.1136/annrheumdis-2016-eular.2465
33 https://doi.org/10.1136/annrheumdis-2017-eular.1260
34 https://doi.org/10.1136/ard.2004.032482
35 https://doi.org/10.1136/ard.2008.094946
36 https://doi.org/10.1177/2040622315582354
37 https://doi.org/10.2217/cer-2018-0075
38 https://doi.org/10.3310/hta10310
39 https://doi.org/10.3310/hta15100
40 https://doi.org/10.3899/jrheum.091315
41 https://doi.org/10.3899/jrheum.100069
42 https://doi.org/10.3899/jrheum.160275
43 schema:datePublished 2018-12
44 schema:datePublishedReg 2018-12-01
45 schema:description Objective: To study cost-effectiveness of an interleukin (IL)-17A inhibitor secukinumab, with other biologics and apremilast in patients with Psoriatic arthritis (PsA) from payer perspective in Finland. Methods: In this semi-Markov model, subcutaneous (SC) secukinumab was compared with SC treatments etanercept and its biosimilar, certolizumab pegol, adalimumab and its biosimilar, golimumab, ustekinumab, intravenous (IV) treatment infliximab, as well as oral non-biologic apremilast. Patients without prior exposure (naïve) to biologics and without moderate to severe psoriasis were considered for secukinumab 150 mg group. Secukinumab 300 mg group included naïve patients with moderate to severe psoriasis and all patients with prior biologic exposure. The PsA Response Criteria (PsARC) at 12-week was primary criteria for treatment response. Other clinical as well as cost related model inputs were derived from relevant clinical trials as well as Finnish publications. The key model outcomes were quality-adjusted life years and incremental cost-effectiveness ratio. An annual 3% discount rate was applied to all future costs and benefits. Model input variations were assessed through sensitivity analyses and alternative scenario analyses. Results: For a lifetime horizon (60 years), secukinumab 150 mg dominated all branded SC biologics and apremilast with highest QALY of 8.01 and lowest lifetime cost of €187,776, while it was cost-effective against IV infliximab among biologic-naïve patients without moderate to severe psoriasis. Secukinumab 300 mg was cost-effective against all branded SC biologics and apremilast and dominated IV infliximab among biologic-naïve patients with moderate to severe psoriasis, while it was cost-effective in biologic experienced patients. With the one-way sensitivity analysis, PsARC response, drug acquisition cost, and health assessment questionnaire score were the most important parameters affecting the outcomes. Across all treatment groups, patients on secukinumab were most likely to achieve highest net monetary benefit than other competitors in probabilistic sensitivity analysis. With alternative scenario analysis, results largely remained unchanged. Conclusions: Secukinumab is a cost-effective treatment for PsA patients from a Finnish payer's perspective.
46 schema:genre research_article
47 schema:inLanguage en
48 schema:isAccessibleForFree true
49 schema:isPartOf N43195b3a3f2d4be9a2c4453ff0869560
50 N43b51fa9a3f04027b89888696ab321e4
51 sg:journal.1032048
52 schema:name Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective
53 schema:pagination 56
54 schema:productId N2464a470090f426b800839facf8e6fc7
55 N258df791a1664b1c938f2961dfaf7bad
56 N87cb2083df6b41c6b890ec19d2b7c543
57 Naccc2c61f2144866b37a89b5408e4dc8
58 Ndd2f8ddc32864fd5850936944b0626a5
59 schema:sameAs https://app.dimensions.ai/details/publication/pub.1109928536
60 https://doi.org/10.1186/s12962-018-0162-3
61 schema:sdDatePublished 2019-04-11T08:13
62 schema:sdLicense https://scigraph.springernature.com/explorer/license/
63 schema:sdPublisher N2618b5dd7a9f47bb8e3c0b27dbca5231
64 schema:url https://link.springer.com/10.1186%2Fs12962-018-0162-3
65 sgo:license sg:explorer/license/
66 sgo:sdDataset articles
67 rdf:type schema:ScholarlyArticle
68 N2464a470090f426b800839facf8e6fc7 schema:name pubmed_id
69 schema:value 30479574
70 rdf:type schema:PropertyValue
71 N258df791a1664b1c938f2961dfaf7bad schema:name nlm_unique_id
72 schema:value 101170476
73 rdf:type schema:PropertyValue
74 N2618b5dd7a9f47bb8e3c0b27dbca5231 schema:name Springer Nature - SN SciGraph project
75 rdf:type schema:Organization
76 N2c10b3fa352b4022b5a75d2a0536b08c schema:name Novartis Finland Oy, Espoo, Finland
77 rdf:type schema:Organization
78 N32e36210277f4f03915870be48a5fcf8 rdf:first sg:person.015705523615.83
79 rdf:rest Nb0a3528bea804f58b8f754ca7e00f395
80 N43195b3a3f2d4be9a2c4453ff0869560 schema:volumeNumber 16
81 rdf:type schema:PublicationVolume
82 N43b51fa9a3f04027b89888696ab321e4 schema:issueNumber 1
83 rdf:type schema:PublicationIssue
84 N64cdfdab4435496fabf43bd5fb15c082 rdf:first sg:person.01015641310.65
85 rdf:rest rdf:nil
86 N87cb2083df6b41c6b890ec19d2b7c543 schema:name dimensions_id
87 schema:value pub.1109928536
88 rdf:type schema:PropertyValue
89 N8f8f442ee9f24e068eb70473b22eb074 rdf:first sg:person.01077653263.36
90 rdf:rest Nb0fd60a2a9964121aa6611ac829f4044
91 Naccc2c61f2144866b37a89b5408e4dc8 schema:name doi
92 schema:value 10.1186/s12962-018-0162-3
93 rdf:type schema:PropertyValue
94 Nb0a3528bea804f58b8f754ca7e00f395 rdf:first sg:person.01065642027.16
95 rdf:rest N64cdfdab4435496fabf43bd5fb15c082
96 Nb0fd60a2a9964121aa6611ac829f4044 rdf:first sg:person.01337337404.54
97 rdf:rest N32e36210277f4f03915870be48a5fcf8
98 Ndd2f8ddc32864fd5850936944b0626a5 schema:name readcube_id
99 schema:value da46f47df5e79cae6a40a9a70b6a669200c3c56d3ddbf83854de43d0f932ac54
100 rdf:type schema:PropertyValue
101 anzsrc-for:14 schema:inDefinedTermSet anzsrc-for:
102 schema:name Economics
103 rdf:type schema:DefinedTerm
104 anzsrc-for:1402 schema:inDefinedTermSet anzsrc-for:
105 schema:name Applied Economics
106 rdf:type schema:DefinedTerm
107 sg:journal.1032048 schema:issn 1478-7547
108 schema:name Cost Effectiveness and Resource Allocation
109 rdf:type schema:Periodical
110 sg:person.01015641310.65 schema:affiliation https://www.grid.ac/institutes/grid.9668.1
111 schema:familyName Martikainen
112 schema:givenName Janne
113 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01015641310.65
114 rdf:type schema:Person
115 sg:person.01065642027.16 schema:affiliation https://www.grid.ac/institutes/grid.464975.d
116 schema:familyName Jain
117 schema:givenName Minal
118 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065642027.16
119 rdf:type schema:Person
120 sg:person.01077653263.36 schema:affiliation N2c10b3fa352b4022b5a75d2a0536b08c
121 schema:familyName Purmonen
122 schema:givenName Timo
123 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077653263.36
124 rdf:type schema:Person
125 sg:person.01337337404.54 schema:affiliation https://www.grid.ac/institutes/grid.434312.3
126 schema:familyName Puolakka
127 schema:givenName Kari
128 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01337337404.54
129 rdf:type schema:Person
130 sg:person.015705523615.83 schema:affiliation https://www.grid.ac/institutes/grid.464975.d
131 schema:familyName Bhattacharyya
132 schema:givenName Devarshi
133 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015705523615.83
134 rdf:type schema:Person
135 sg:pub.10.1007/s10067-016-3425-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042078868
136 https://doi.org/10.1007/s10067-016-3425-4
137 rdf:type schema:CreativeWork
138 sg:pub.10.1007/s10198-011-0335-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1037467100
139 https://doi.org/10.1007/s10198-011-0335-x
140 rdf:type schema:CreativeWork
141 sg:pub.10.1007/s40265-014-0191-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1052835422
142 https://doi.org/10.1007/s40265-014-0191-y
143 rdf:type schema:CreativeWork
144 sg:pub.10.1007/s40271-014-0075-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1015256079
145 https://doi.org/10.1007/s40271-014-0075-y
146 rdf:type schema:CreativeWork
147 sg:pub.10.1007/s40744-016-0029-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1002336273
148 https://doi.org/10.1007/s40744-016-0029-z
149 rdf:type schema:CreativeWork
150 sg:pub.10.1038/nrrheum.2017.188 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092816761
151 https://doi.org/10.1038/nrrheum.2017.188
152 rdf:type schema:CreativeWork
153 sg:pub.10.1186/1471-2474-15-26 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011167965
154 https://doi.org/10.1186/1471-2474-15-26
155 rdf:type schema:CreativeWork
156 sg:pub.10.1186/2193-1801-2-531 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039556570
157 https://doi.org/10.1186/2193-1801-2-531
158 rdf:type schema:CreativeWork
159 https://app.dimensions.ai/details/publication/pub.1076612913 schema:CreativeWork
160 https://app.dimensions.ai/details/publication/pub.1078323662 schema:CreativeWork
161 https://app.dimensions.ai/details/publication/pub.1079165331 schema:CreativeWork
162 https://doi.org/10.1002/acr.23111 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019018398
163 rdf:type schema:CreativeWork
164 https://doi.org/10.1002/art.39573 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005700908
165 rdf:type schema:CreativeWork
166 https://doi.org/10.1016/j.jval.2010.10.016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020791101
167 rdf:type schema:CreativeWork
168 https://doi.org/10.1016/j.jval.2015.09.2852 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015684295
169 rdf:type schema:CreativeWork
170 https://doi.org/10.1016/s0140-6736(15)61134-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040399320
171 rdf:type schema:CreativeWork
172 https://doi.org/10.1046/j.1365-2133.2002.04920.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1005696098
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1056/nejmoa1412679 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035341201
175 rdf:type schema:CreativeWork
176 https://doi.org/10.1080/13696998.2017.1384737 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091933859
177 rdf:type schema:CreativeWork
178 https://doi.org/10.1093/rheumatology/keg107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026122648
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1093/rheumatology/kem221 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042257987
181 rdf:type schema:CreativeWork
182 https://doi.org/10.1093/rheumatology/ker245 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033865184
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1093/rheumatology/kex452 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092758382
185 rdf:type schema:CreativeWork
186 https://doi.org/10.1097/00005650-199711000-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1060223465
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1136/annrheumdis-2011-200350 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009950017
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1136/annrheumdis-2012-202424 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030930080
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1136/annrheumdis-2014-206418 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013200417
193 rdf:type schema:CreativeWork
194 https://doi.org/10.1136/annrheumdis-2015-208337 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022767391
195 rdf:type schema:CreativeWork
196 https://doi.org/10.1136/annrheumdis-2016-eular.2465 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062760399
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1136/annrheumdis-2017-eular.1260 schema:sameAs https://app.dimensions.ai/details/publication/pub.1095975872
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1136/ard.2004.032482 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002609767
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1136/ard.2008.094946 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035839107
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1177/2040622315582354 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064083933
205 rdf:type schema:CreativeWork
206 https://doi.org/10.2217/cer-2018-0075 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107093501
207 rdf:type schema:CreativeWork
208 https://doi.org/10.3310/hta10310 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071138932
209 rdf:type schema:CreativeWork
210 https://doi.org/10.3310/hta15100 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071139223
211 rdf:type schema:CreativeWork
212 https://doi.org/10.3899/jrheum.091315 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071542120
213 rdf:type schema:CreativeWork
214 https://doi.org/10.3899/jrheum.100069 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030409323
215 rdf:type schema:CreativeWork
216 https://doi.org/10.3899/jrheum.160275 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008779147
217 rdf:type schema:CreativeWork
218 https://www.grid.ac/institutes/grid.434312.3 schema:alternateName Etelä-Karjalan sosiaali ja terveyspiiri
219 schema:name South Karelia Social and Health Care District, Lappeenranta, Finland
220 rdf:type schema:Organization
221 https://www.grid.ac/institutes/grid.464975.d schema:alternateName Novartis (India)
222 schema:name Novartis Product Life Cycle Services-NBS, Novartis Healthcare Private Limited, Hyderabad, India
223 rdf:type schema:Organization
224 https://www.grid.ac/institutes/grid.9668.1 schema:alternateName University of Eastern Finland
225 schema:name School of Pharmacy, University of Eastern Finland, Kuopio, Finland
226 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...